Previous Close | 9.16 |
Open | 9.18 |
Bid | 6.00 x 800 |
Ask | 10.79 x 3200 |
Day's Range | 9.18 - 10.65 |
52 Week Range | 6.05 - 45.56 |
Volume | |
Avg. Volume | 203,491 |
Market Cap | 468.54M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.36 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.43 |
Subscribe to Yahoo Finance Plus to view Fair Value for GLUE
– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors – – Cash Runway into Late 2024 with $299.5 Million in Cash, Cash Equivalents, Restricted Cash and Marketable Securities as of June 30, 2022 – BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business hig
The BPDA cleared the way last summer for a roughly 220,000-square-foot lab and research-and-development site in a neighborhood that is seeing an influx of life sciences space.
– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Track to File Investigational New Drug (IND) Application Mid-year – – Initiated Research with École Polytechnique Fédérale de Lausanne (EPFL); Collaboration to Broaden Monte Rosa’s AI Capabilities – BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company dev